USPTO serial 85317171
SOLBRI
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- TENG, SIMON
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with SOLBRI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and substances for the treatment of skin disorders, diseases, conditions and ailments; pharmaceutical preparations and products for use in dermatology; antifungal preparations; pharmaceutical preparations and substances for the treatment of eye disorders, diseases, conditions and ailments; pharmaceutical preparations and products for ophthalmological use; pharmaceutical preparations and substances for the treatment of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety, depression, depressive disorders and mental illness; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardiovascular system; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations and substances for the treatment of infectious diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations and substances for use in chemotherapy; pharmaceutical preparations and substances for use in urology; pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, anti-inflammatories and pain relief medication; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances for the treatment of fungal infections, onychomycosis, tinea infections, and similar diseases of the skin and nails; pharmaceutical preparations and substances for use in dermatological conditions | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Valeant International (Barbados) SRL
- Other trademarks owned by Valeant International (Barbados) SRL
- Other trademarks owned by Valeant International Bermuda
- Other trademarks in Class 005
- Similar marks named SOLBRI
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 16, 2025 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Aug 1, 2016 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 1, 2016 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 3, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 20, 2016 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 19, 2016 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Dec 21, 2015 | EXT3 | SOU EXTENSION 3 FILED | — |
| Dec 21, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 14, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 11, 2015 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 29, 2015 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 29, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 19, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 18, 2015 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Feb 12, 2015 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 21, 2015 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Dec 18, 2014 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 18, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 1, 2014 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 6, 2014 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 6, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 16, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 1, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Apr 1, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 13, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 12, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 12, 2014 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jan 22, 2014 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 22, 2014 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 30, 2013 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Sep 30, 2013 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 30, 2013 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 12, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 12, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 11, 2013 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 18, 2013 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 18, 2013 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 18, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 7, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 7, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 27, 2013 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Aug 28, 2012 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Aug 28, 2012 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Aug 28, 2012 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Aug 27, 2012 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Aug 27, 2012 | ALIE | ASSIGNED TO LIE | — |
| Aug 1, 2012 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Feb 24, 2012 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Feb 24, 2012 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Feb 24, 2012 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Feb 23, 2012 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 23, 2012 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 23, 2012 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 24, 2011 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 24, 2011 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 24, 2011 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 24, 2011 | DOCK | ASSIGNED TO EXAMINER | — |
| May 16, 2011 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 13, 2011 | NWAP | NEW APPLICATION ENTERED | — |